undamentalytics Newsletter
Sign in

Molina Healthcare, Inc. (MOH) stock

Add to watchlist

Add holding +

NYSE: MOH NYSE Managed Health Care Next results ~January 13, 2027

D Fundamentals grade

Molina Healthcare, Inc. is a US-listed company in the managed health care industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Molina Healthcare files

10-Q filed October 22: Molina Healthcare

Revenue for the twelve months to September 2026 reached $44.1bn, a decline of 0.9% on a year earlier. That marks a slowdown from the 2.6% growth recorded a quarter earlier, and it ranks Molina 855 of the 934 companies we cover on growth. On the supportive side, the diluted share count is down 6.1% year on year, which lifts the claim attaching to each remaining share. Our fundamentals grade shifts from D to C+. Despite that upgrade, our model value drops sharply, from $449 to $251 a share. The shares currently trade at $217, leaving the stock below our revised estimate but well short of the earlier figure.

Our model value for Molina Healthcare is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 22, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Molina Healthcare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $44.5bn, up 2.6% on a year earlier, slower than 7.7% a quarter earlier. That puts it 749 of 931 for growth among all the companies we cover. The diluted share count is down 7.8% on a year earlier, which lifts each remaining share.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 13, 2027 (estimated)

Molina Healthcare, Inc.'s trailing-twelve-month revenue fell 0.9% year on year, with a free-cash-flow margin of 0.5%. Where it stands out: change in share count of -6.1% ranks 1 of 8 managed health care companies we cover. Where it lags: revenue growth of -0.9% ranks 8 of 8 managed health care companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -0.9% (-3.5pp vs the prior quarter), the 7th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 6.1% in a year, so each share owns more of the business.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 11.5% over 90 days.

Things to watch

  • Revenue shrinking. Revenue fell 0.9% over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 50% and a beta of -0.2 against the S&P 500.
  • Growth easing. The growth rate is 3.5 points lower than a quarter earlier.
  • Below peers: change in growth rate. Change in growth rate of -3.5pp ranks 7 of 8 managed health care companies we cover (median -1.3pp).
  • Below peers: operating margin. Operating margin of 0.4% ranks 7 of 8 managed health care companies we cover (median 1.9%).

Latest results: FY2026 Q3

Filed October 22, 2026
Earnings per share
$0.89 against an average estimate of $0.79: beat by 12.0%
Revenue
$11.08bn, down 3.4% on a year earlier
Share reaction
-1.4% in the first session after the results on October 21, 2026, against -0.7% for the S&P 500
Guidance given
premium revenue $42bn (full year 2026); adjusted earnings per diluted share $5.25 (full year 2026)
Next report
October 21, 2026; average EPS estimate $0.51

Molina Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.8%
  • 1 week+1.8%
  • 1 month+10.0%
  • This year+20.1%
  • 1 year+36.2%
  • 5 years-31.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$44.1B
Operating margin
0.4%
Net margin
-0.1%
EPS (TTM, diluted)
$-0.94

Growth

Revenue growth
−0.9%
Change in growth rate
−3.5 pts
Share count change
−6.1%

Earnings

Last results
October 21, 2026
Next results (est.)
January 13, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Results
  3. Guidance
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Molina Healthcare, Inc. valuation models and calculator

No model value for Molina Healthcare, Inc. at the moment. Current status: valuation models disagree too widely to rate. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valuation models disagree too widely to rate: held for review.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Molina Healthcare, Inc. as a health plan, with every model that fits that kind of business. Cost of equity 7%: the 10-year Treasury yield (4.9%) plus a beta of 0.46 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$130 ~$110–$150 Primary model, counts double
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$470 ~$300–$770 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$350 ~$280–$460 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Molina Healthcare, Inc. with health plans in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

40 /100

Weak moat

How hard Molina Healthcare's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 8 / 20

    Net income has been a median 5.9% of total assets over 10 years.

  • Pricing power 8 / 20

    Gross margin has been a median 14.4%, moving by 2.5 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 3.8%; its worst year was -1.5%.

  • Cash conversion 9 / 20

    Free cash flow was positive in 8 of 10 years, at a median 2.2% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 13.1% over five years; stock-based pay has been a median 0.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (44 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $5.27 −52% $44.7bn −2%
Next $9.54 +177% $47.7bn +7%

Next year's EPS estimate has moved +11.5% in 90 days, across 6 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.6% on 90 days ago. In the last 30 days, 1 analyst raised Molina Healthcare, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Molina Healthcare, Inc., last 90 days
$4.00 $6.00 $8.00 $10.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $5.24 Current fiscal year, 60 days ago: $5.24 Current fiscal year, 30 days ago: $5.25 Current fiscal year, 7 days ago: $5.25 Current fiscal year, Now: $5.27 $5.27 Next fiscal year, 90 days ago: $8.55 Next fiscal year, 60 days ago: $8.55 Next fiscal year, 30 days ago: $8.55 Next fiscal year, 7 days ago: $8.55 Next fiscal year, Now: $9.54 $9.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $5.24$8.55
60 days ago $5.24$8.55
30 days ago $5.25$8.55
7 days ago $5.25$8.55
Now $5.27$9.54

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.79 $0.89 +12.0%
Jun 2026 $1.40 $1.51 +7.8%
Mar 2026 $1.91 $2.35 +23.0%
Dec 2025 $0.33 −$2.75 −921.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 21, 2026
  • premium revenue full year 2026 about $42bn Maintained
    “The Company reaffirmed its full year 2026 guidance of expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.25 per diluted share.” source
  • adjusted earnings per diluted share full year 2026 about $5.25 Non-GAAP Maintained
    “The Company expects its full year 2026 GAAP earnings to be at least $2.38 per diluted share and reaffirmed its full year 2026 adjusted earnings of at least $5.25 per diluted share.” source
  • GAAP earnings per diluted share full year 2026 about $2.38 GAAP
    “The Company expects its full year 2026 GAAP earnings to be at least $2.38 per diluted share and reaffirmed its full year 2026 adjusted earnings of at least $5.25 per diluted share.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

19 analysts, Oct 2026
Buy421%
Hold1474%
Sell15%

Monthly trend

  1. Oct 202631419
  2. Sep 202631419
  3. Aug 202631519
  4. Jul 202631519

Counts of recommendations published by analysts covering Molina Healthcare, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.7%
of tradable shares
Days to cover
4.28
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.4%
of shares
Employees
19,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +36.2%

$153.06 on October 31, 2025 to $208.45

ThenNowEffect
Revenue (last 12 months) $43.4bn $44.5bn +2.6%
P/S multiple 0.2x 0.2x +22.4%
Share count 56m 51m +8.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −38.2%

$337.43 on November 3, 2023 to $208.45

ThenNowEffect
Revenue (last 12 months) $32.6bn $44.5bn +36.5%
P/S multiple 0.6x 0.2x −60.1%
Share count 58m 51m +13.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MOH+50%+4%+9%−19%−40%+20%
Industry peers (median)+37%−1%−7%−2%−3%+62%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MOH75%42%58%33%42%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MOH−17%−28%−21%−35%−62%−39%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 71% from March 19, 2024 to February 11, 2026. Getting back needed a 242% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$122.65 – $242.88
From 52-week high
−14.2%
vs 50-day average
+3.8%
vs 200-day average
+12.7%
Volatility (1 year)
50%
Beta vs S&P 500
-0.18

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±10.9%
After a week
4 up, 8 down
typical move ±14.7%
After a month
4 up, 7 down
typical move ±14.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 21, 2026 −1.4% −0.7% −9.8% —
July 22, 2026 −11.6% −1.3% −12.1% −13.1%
April 22, 2026 +15.7% +0.6% +30.1% +20.0%
February 5, 2026 −26.0% +0.6% −28.8% −18.0%
October 22, 2025 −18.2% +0.1% −18.6% −31.7%
July 23, 2025 −12.4% +0.9% −11.4% −4.3%
July 7, 2025 −3.6% −0.8% −8.6% −35.2%
April 23, 2025 −2.3% +3.7% +1.8% −3.5%
February 5, 2025 −9.6% +0.8% −15.5% +3.8%
October 23, 2024 +14.0% −0.7% +14.2% +4.3%
July 24, 2024 +13.0% −2.8% +19.0% +19.9%
April 24, 2024 −3.0% −0.4% −6.7% −6.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Molina Healthcare, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Molina Healthcare, Inc.
$30B $35B $40B $45B $50B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $34.1B Revenue (TTM), FY24 Q1: $35.9B Revenue (TTM), FY24 Q2: $37.4B Revenue (TTM), FY24 Q3: $39.2B Revenue (TTM), FY24 Q4: $40.7B Revenue (TTM), FY25 Q1: $41.9B Revenue (TTM), FY25 Q2: $43.4B Revenue (TTM), FY25 Q3: $44.6B Revenue (TTM), FY25 Q4: $45.4B Revenue (TTM), FY26 Q1: $45.1B Revenue (TTM), FY26 Q2: $44.5B Revenue (TTM), FY26 Q3: $44.1B $44.1B

Source: SEC EDGAR filings. Retrieved October 23, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $34.1B
FY24 Q1 $35.9B
FY24 Q2 $37.4B
FY24 Q3 $39.2B
FY24 Q4 $40.7B
FY25 Q1 $41.9B
FY25 Q2 $43.4B
FY25 Q3 $44.6B
FY25 Q4 $45.4B
FY26 Q1 $45.1B
FY26 Q2 $44.5B
FY26 Q3 $44.1B
Revenue growth, TTM YoY Molina Healthcare, Inc.
-10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 6.6% Revenue growth, TTM YoY, FY24 Q1: 10.8% Revenue growth, TTM YoY, FY24 Q2: 14.7% Revenue growth, TTM YoY, FY24 Q3: 17.9% Revenue growth, TTM YoY, FY24 Q4: 19.3% Revenue growth, TTM YoY, FY25 Q1: 16.8% Revenue growth, TTM YoY, FY25 Q2: 16.1% Revenue growth, TTM YoY, FY25 Q3: 13.7% Revenue growth, TTM YoY, FY25 Q4: 11.7% Revenue growth, TTM YoY, FY26 Q1: 7.7% Revenue growth, TTM YoY, FY26 Q2: 2.6% Revenue growth, TTM YoY, FY26 Q3: -0.9% -0.9%

Source: SEC EDGAR filings. Retrieved October 23, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 6.6%
FY24 Q1 10.8%
FY24 Q2 14.7%
FY24 Q3 17.9%
FY24 Q4 19.3%
FY25 Q1 16.8%
FY25 Q2 16.1%
FY25 Q3 13.7%
FY25 Q4 11.7%
FY26 Q1 7.7%
FY26 Q2 2.6%
FY26 Q3 -0.9%
Operating margin (TTM) Molina Healthcare, Inc.
0% 2% 4% 6% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 4.6% Operating margin (TTM), FY24 Q1: 4.3% Operating margin (TTM), FY24 Q2: 4.1% Operating margin (TTM), FY24 Q3: 4.2% Operating margin (TTM), FY24 Q4: 4.2% Operating margin (TTM), FY25 Q1: 4.1% Operating margin (TTM), FY25 Q2: 3.8% Operating margin (TTM), FY25 Q3: 3.0% Operating margin (TTM), FY25 Q4: 1.7% Operating margin (TTM), FY26 Q1: 1.0% Operating margin (TTM), FY26 Q2: 0.5% Operating margin (TTM), FY26 Q3: 0.4% 0.4%

Source: SEC EDGAR filings. Retrieved October 23, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 4.6%
FY24 Q1 4.3%
FY24 Q2 4.1%
FY24 Q3 4.2%
FY24 Q4 4.2%
FY25 Q1 4.1%
FY25 Q2 3.8%
FY25 Q3 3.0%
FY25 Q4 1.7%
FY26 Q1 1.0%
FY26 Q2 0.5%
FY26 Q3 0.4%
FCF margin (TTM) Molina Healthcare, Inc.
-2% 0% 2% 4% 6% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 4.6% FCF margin (TTM), FY24 Q1: 2.5% FCF margin (TTM), FY24 Q2: 0.5% FCF margin (TTM), FY24 Q3: 0.2% FCF margin (TTM), FY24 Q4: 1.3% FCF margin (TTM), FY25 Q1: 1.3% FCF margin (TTM), FY25 Q2: 1.0% FCF margin (TTM), FY25 Q3: -1.3% FCF margin (TTM), FY25 Q4: -1.4% FCF margin (TTM), FY26 Q1: 0.6% FCF margin (TTM), FY26 Q2: 0.6% FCF margin (TTM), FY26 Q3: 0.5% 0.5%

Source: SEC EDGAR filings. Retrieved October 23, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 4.6%
FY24 Q1 2.5%
FY24 Q2 0.5%
FY24 Q3 0.2%
FY24 Q4 1.3%
FY25 Q1 1.3%
FY25 Q2 1.0%
FY25 Q3 -1.3%
FY25 Q4 -1.4%
FY26 Q1 0.6%
FY26 Q2 0.6%
FY26 Q3 0.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 3.7 4.1 4.5 5.9 6.6 9.7 14.2 17.8 19.9 18.9 16.8 19.4 27.8 32.0 34.1 40.7 45.4 44.1
Gross profit — — — — 0.8 1.0 1.5 1.7 1.8 2.5 2.3 2.5 4.1 4.8 5.4 6.2 5.9 5.6
EBITDA 0.1 0.2 0.2 0.1 0.2 0.3 0.5 0.5 −0.4 1.3 1.1 1.2 1.2 1.3 1.7 1.9 1.0 0.3
Operating income 0.1 0.1 0.1 0.0 0.1 0.2 0.4 0.3 −0.6 1.1 1.0 1.1 1.0 1.2 1.6 1.7 0.8 0.2
Net income 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 −0.5 0.7 0.7 0.7 0.7 0.8 1.1 1.2 0.5 −0.0
Diluted EPS $0.79 $1.32 $0.45 $0.21 $1.13 $1.29 $2.58 $0.92 −$9.07 $10.61 $11.47 $11.23 $11.25 $13.55 $18.77 $20.42 $8.92 −$0.94
Growth (year on year)
Revenue — +11.4% +11.1% +30.3% +11.4% +46.7% +46.7% +25.4% +11.8% −5.0% −10.9% +15.4% +43.0% +15.1% +6.6% +19.3% +11.7% −0.9%
EBITDA — +84.1% +26.8% −43.0% +92.7% +41.6% +56.9% −4.9% −177.3% — −9.9% +2.9% −1.3% +17.2% +29.3% +8.5% −48.4% −78.1%
Operating income — — +29.4% −69.7% — +40.9% — −20.9% — — −7.7% +3.3% −5.4% +15.0% +34.1% +8.5% −54.2% −87.0%
Net income — — — — — — — — — — +4.2% −8.7% −2.1% +20.2% +37.8% +8.1% −60.0% —
Diluted EPS — — — — — — — — — — +8.1% −2.1% +0.2% +20.4% +38.5% +8.8% −56.3% —
Margins
Gross margin — — — — 12.8% 10.3% 10.8% 9.7% 9.1% 13.3% 13.7% 12.8% 14.6% 15.0% 15.9% 15.3% 13.1% 12.6%
EBITDA margin 2.5% 4.1% 4.6% 2.0% 3.5% 3.4% 3.6% 2.7% −1.9% 6.7% 6.7% 6.0% 4.1% 4.2% 5.1% 4.7% 2.1% 0.8%
Operating margin 1.4% 2.6% 3.0% 0.7% 2.1% 2.0% 2.7% 1.7% −2.8% 6.0% 6.2% 5.6% 3.7% 3.7% 4.6% 4.2% 1.7% 0.4%
Net margin 0.8% 1.3% 0.5% 0.2% 0.8% 0.6% 1.0% 0.3% −2.6% 3.7% 4.4% 3.5% 2.4% 2.5% 3.2% 2.9% 1.0% −0.1%
Free-cash-flow margin — — — — — 9.8% 7.0% 2.8% 3.6% −1.8% 2.2% 9.4% 7.4% 2.1% 4.6% 1.3% −1.4% 0.5%
Cash flow
Cash from operations 0.2 0.2 0.2 0.3 0.2 1.1 1.1 0.7 0.8 −0.3 0.4 1.9 2.1 0.8 1.7 0.6 −0.5 0.3
Capital spending — — — — — 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Free cash flow — — — — — 0.9 1.0 0.5 0.7 −0.3 0.4 1.8 2.0 0.7 1.6 0.5 −0.6 0.2
Stock-based pay 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1
Free cash flow after stock pay — — — — — 0.9 1.0 0.5 0.7 −0.4 0.3 1.8 2.0 0.6 1.5 0.4 −0.7 0.1
Balance sheet
Cash 0.5 0.5 0.5 0.8 0.9 1.5 2.3 2.8 3.2 2.8 2.5 4.2 4.4 4.0 4.8 4.7 4.2 4.5
Total debt 0.0 0.2 0.2 0.3 0.7 0.9 1.6 1.6 2.2 1.5 1.3 2.2 2.2 2.2 2.2 3.0 3.8 3.8
Net debt (negative = net cash) −0.5 −0.3 −0.3 −0.5 −0.2 −0.7 −0.7 −1.2 −1.0 −1.4 −1.2 −2.0 −2.2 −1.8 −2.6 −1.7 −0.5 −0.7
Diluted shares 39m 42m 46m 47m 47m 48m 56m 56m 56m 67m 64m 60m 59m 59m 58m 58m 53m 51m
Returned to shareholders
Buybacks 0.0 0.0 0.0 0.0 0.1 0.0 0.0 — 0.0 0.0 0.0 0.6 0.1 0.4 0.0 1.0 1.0 0.0
Total returned 0.0 0.0 0.0 0.0 0.1 0.0 0.0 — 0.0 0.0 0.0 0.6 0.1 0.4 0.0 1.0 1.0 0.0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$2B
Diluted share count
−6.1%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value

Competitors: side by side with peers

Closest by revenue in managed health care
Last 12 months unless stated MOH OSCR HUM ELV CNC ALHC Median
Revenue, last 12 months $44.1bn $15.3bn $145.7bn $201.8bn $203.9bn $4.9bn $94.9bn
Revenue growth, last 12 months −0.9% 42.8% 18.3% 3.6% 9.7% 35.9% 14.0%
Revenue growth, 3-year average 9.9% 45.6% 13.8% 6.2% 10.7% 42.2% 12.3%
Revenue growth, latest quarter −3.4% 70.4% 26.2% 1.4% 1.9% 36.7% 14.1%
Gross margin 12.6% — — 89.0% 7.9% — 24.9%
Operating margin 0.4% 4.1% 1.9% 2.7% 0.5% 0.9% 1.4%
Operating margin, 3-year average 2.5% 1.2% 2.5% 3.8% −0.3% −1.3% 1.8%
Net margin −0.1% 3.6% 0.9% 2.5% 0.7% 0.6% 0.8%
Cash from operations / revenue 0.8% 28.8% 1.7% 3.8% 2.3% 2.2% 2.7%
Free-cash-flow margin 0.5% 28.6% 1.3% 3.2% 1.9% 1.6% 2.5%
Free-cash-flow margin, 3-year average −0.2% 14.4% −0.4% 1.9% 1.3% −0.6% 0.6%
Stock pay / revenue 0.2% 0.5% 0.2% 0.1% 0.1% 1.3% 0.2%
Change in share count −6.1% 12.1% 0.1% −3.3% −0.4% 1.6% −0.2%

Median of all 8 companies we cover in managed health care. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

8 managed health care companies
Measure Company Peer median Rank
Revenue growth Growth -0.9% 18.3% 8 of 8
Change in growth rate Growth -3.5pp -1.3pp 7 of 8
Operating margin Profitability 0.4% 1.9% 7 of 8
Net margin Profitability -0.1% 0.9% 7 of 8
Stock pay as % of revenue Cash generation 0.2% 0.2% 5 of 8
Long-term debt as % of assets Balance sheet 24.1% 22.4% 6 of 7
Change in share count Balance sheet -6.1% 0.1% 1 of 8

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$12.8B
Institutions reporting
598
Shares held vs prior quarter
▲ 1.5%
Positions opened / closed
148 / 73

Top buyers and sellers, Q2 2026: 359 institutions bought and 245 sold ; the biggest buyer was Lingotto Investment Management LLP (+2.5M shares) and the biggest seller FMR LLC (−1.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $1.5B 6.6M 11.7% ▲ 3.2%
AQR Capital Management LLC $807M 3.6M 6.3% ▲ 24.3%
Vanguard Portfolio Management LLC $638M 2.8M 5.0% 0.0%
Capital World Investors $586M 2.6M 4.6% ▼ 19.9%
Lingotto Investment Management LLP $574M 2.5M 4.5% New
Vanguard Capital Management LLC $539M 2.4M 4.2% ▲ 1.9%
Victory Capital Management Inc $453M 2.0M 3.5% ▼ 4.4%
FMR LLC $428M 1.9M 3.3% ▼ 41.6%
State Street Corp $401M 1.8M 3.1% ▲ 1.4%
Dimensional Fund Advisors LP $319M 1.4M 2.5% ▼ 0.1%
Goldman Sachs Group Inc $299M 1.3M 2.3% ▲ 79.7%
Wellington Management Group LLP $290M 1.3M 2.3% ▲ 11.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Molina Healthcare, Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $100,128 1 trade by 1 insider, last 12 months Insider sales History → $3.6M 4 trades by 4 insiders · 0% under pre-set plans
Net ▼ $3.5M net selling
Insider Date Trade Shares Price Value
Hebert Maurice Chief Accounting Officer May 14, 2026 Sell 600 $191.55 $114,930
Barlow Jeff D. Chief Legal Officer May 11, 2026 Sell 17,811 $186.12 $3.3M
Romney Ronna Director March 12, 2026 Sell 506 $146.92 $74,342
Zoretic Richard C Director February 11, 2026 Buy 800 $125.16 $100,128
Schapiro Richard M Director November 24, 2025 Sell 357 $143.02 $51,058

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 11 trades and filings

In the last 12 months, 1 member of Congress disclosed 0 purchases and 1 sale of Molina Healthcare, Inc. shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (partial), $1,001 - $15,000, traded November 12, 2025, filed December 15, 2025
  • Byron Donalds(R-FL 19):Sale (full), $1,001 - $15,000, traded September 4, 2025, filed October 7, 2025
  • Byron Donalds(R-FL 19):Sale (full), $1,001 - $15,000, traded September 4, 2025, filed October 7, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 13, 2027 estimated from the company's past filing pattern, not announced

  • October 21, 2026
  • July 22, 2026
  • April 22, 2026
  • February 5, 2026
  • October 22, 2025
  • July 23, 2025

Recent SEC filings

Data status

When each part of this page on Molina Healthcare, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Molina Healthcare, Inc. in brief

What does Molina Healthcare, Inc. do?
Molina Healthcare, Inc. is a US-listed company in the managed health care industry. Its financial year ends in December.
What is Molina Healthcare, Inc.'s stock ticker?
Molina Healthcare, Inc. trades under the ticker MOH on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Molina Healthcare, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Molina Healthcare, Inc. reported revenue of $44.1B, 0.9% lower than a year earlier, according to its SEC filings.
What is Molina Healthcare, Inc.'s free cash flow?
Molina Healthcare, Inc.'s free-cash-flow margin is 0.5% of revenue over the trailing twelve months.
Who are Molina Healthcare, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., AQR Capital Management LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Molina Healthcare, Inc. buying back stock, and does it pay a dividend?
Molina Healthcare, Inc. spent $0 on share repurchases over the trailing twelve months, and its diluted share count fell 6.1% over the year.
What is Molina Healthcare, Inc.'s market cap?
On November 2, 2026, Molina Healthcare, Inc.'s market capitalisation was about $10.7B and net debt of -$708M. Market figures come from third-party market data and may be delayed.
Who are Molina Healthcare, Inc.'s competitors?
In our Managed Health Care peer group, the companies closest to Molina Healthcare, Inc. are Oscar Health, Inc., Humana, Elevance Health, Centene Corporation and Alignment Healthcare, Inc. The side-by-side comparison below sets their revenue, margins and growth against Molina Healthcare, Inc.'s.
Are insiders buying or selling Molina Healthcare, Inc. stock?
Over the last 12 months, Molina Healthcare, Inc.'s directors and officers reported 1 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Molina Healthcare, Inc.'s next earnings date?
Around January 13, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Molina Healthcare, Inc. announces its own schedule.